🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Marksans Pharma Limited MARKSANS NSEPHARMA

Healthcare · Drug Manufacturers - General · India
https://marksanspharma.com
Company Profile ↓
₹326.75
+74.98% 1Y
Mkt Cap₹14,807.13 Cr
P/E35.44
P/B4.10
Div. Yield0.33%
52W High₹332.50
52W Low₹156.46
Book Value₹66.71
EPS (TTM)₹9.22

Company Overview

Marksans Pharma Limited, together with its subsidiaries, engages in the research, manufacturing, marketing, and sale of pharmaceutical formulations in the United States, North America, Europe, the United Kingdom, Australia, New Zealand, and internationally. The company offers products in the pain management, cardiovascular, central nervous system, anti-diabetic, gastrointestinal, analgesics, upper respiratory, ear care, skincare, anticancer, anti-ulcerative, anti-allergy, antiviral, dietary, cardiac, dermatology, antihistamines, anti-fungal, anti-viral, laxatives, and cold and cough therapeutic areas. Its product portfolio includes plain, enteric-coated, and film coated tablets; soft gelatin and hard capsules; oral liquids; and ointments, as well as creams and liquids. The company provides its products to supermarkets, high street retailers, pharmacy chains, and wholesalers. Marksans Pharma Limited was incorporated in 1992 and is headquartered in Mumbai, India.

Why Investors Should Care

Healthy Capital Returns

Return on capital employed stands at 17.5%.

Consistent Profit Growth

Net profit has compounded at 16.2% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 16.8% CAGR over the past five years.

Reasonable Valuation

Trades at a P/E of 35.4, below the sector median of 41.6.

Healthy Margins

Operating margin of 17.0% supports profitability.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.11.

Recent Developments

  • Mar 2026 Revenue of ₹2,950.94 Cr (+12.5% YoY); net profit ₹417.90 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +12.5%, earnings +9.8%.
  • 5-Year Trend Long-term compounding — revenue CAGR 16.8%, profit CAGR 16.2%.

Growth & Price Performance

Compounded Sales Growth

5 Years:16.85%
1 Year:12.51%

Compounded Profit Growth

5 Years:16.21%
1 Year:9.81%

Stock Price Performance

1 Year:+74.98%
6 Months:+91.55%
3 Months:+29.63%
1 Month:+21.85%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 97% of range
₹156.46 ₹332.50
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)61.53 · Neutral
Price Performance
1M+21.85%
3M+29.63%
6M+91.55%
1Y+74.98%
Valuation vs Sector

P/E of 35.44 is below the sector median of 41.64 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 16.8% over 5 years.
  • Profit CAGR of 16.2% over 5 years.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
35.44
Industry PE
41.64
Forward P/E
24.20
PEG Ratio
1.12
Book Value
₹66.71
Price to Book
4.10
P/S
4.21
EV/EBITDA
20.89
Dividend Yield
0.33%

Growth (CAGR)

Revenue 5Y
16.85%
Profit 5Y
16.21%
Revenue (YoY)
12.51%
Earnings (YoY)
9.81%

Profitability & Returns

ROCE
17.54%
ROE
13.82%
ROA
10.82%
Profit Margin
14.16%
Op Margin
17.02%
Gross Margin
56.72%
EPS (Latest Qtr)
₹3.27
EPS (TTM)
₹9.22

Balance Sheet & Liquidity

Debt/Equity
0.11
Quick Ratio
3.32
Current Ratio
5.17
Debt
₹343.38 Cr
Total Assets
₹3,860.90 Cr
Current Assets
₹2,722.74 Cr
Working Capital
₹2,195.65 Cr

Ownership

Promoter Holding
43.87%
Chg in Prom Hold
-0.18%
FII / Inst Holding
18.34%
Chg in FII Hold
0.05%

Financial Snapshot

Enterprise Value
₹14,807.13 Cr
Total Revenue (TTM)
₹2,950.94 Cr
EBITDA
₹683.31 Cr
Free Cash Flow
₹327.60 Cr
Operating Cash Flow
₹458.12 Cr
Shares Outstanding
₹45.32 Cr
Gross Margin
56.72%
Payout Ratio
8.68%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 MARKSANS Marksans Pharma Limited NSEPHARMA 326.75 35.44 ₹14,807.13 Cr 0.33% 17.54% 13.82% 16.85% 16.21%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,899.00 39.73 ₹4.56 L Cr 0.82% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 9,100.00 94.06 ₹2.42 L Cr 0.36% 18.96% 15.32% 10.98% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,857.00 75.99 ₹1.64 L Cr 0.77% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,650.00 64.10 ₹1.24 L Cr 0.22% 19.20% 20.48% 14.85% 33.34%
6 LENSKART LENSKART SOLUTIONS LTD NIFTY_MIDNSEPHARMA 684.90 236.17 ₹1.19 L Cr 0.00% 7.21% 5.65% 35.38% 66.99%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,120.00 22.36 ₹1.13 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,385.00 28.85 ₹1.12 L Cr 0.88% 14.86% 11.27% 7.23% 11.45%
9 LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA 1,840.00 111.85 ₹99,333.61 Cr 0.13% 19.53% 16.77% 3.77% 4.00%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 486.00 Cr500.00 Cr531.00 Cr586.00 Cr560.00 Cr591.00 Cr642.00 Cr682.00 Cr708.46 Cr619.99 Cr720.41 Cr754.43 Cr856.11 Cr
Cost of Revenue --------325.22 Cr261.81 Cr308.59 Cr316.22 Cr390.65 Cr
Gross Profit --------383.24 Cr358.18 Cr411.82 Cr438.20 Cr465.46 Cr
Operating Expenses 376.00 Cr398.00 Cr417.00 Cr453.00 Cr450.00 Cr462.00 Cr495.00 Cr543.00 Cr279.05 Cr281.15 Cr294.24 Cr301.79 Cr294.33 Cr
Operating Income 96.00 Cr88.00 Cr96.00 Cr111.00 Cr89.00 Cr108.00 Cr127.00 Cr118.00 Cr104.19 Cr77.02 Cr117.58 Cr136.41 Cr171.13 Cr
EBITDA 110.00 Cr102.00 Cr114.00 Cr133.00 Cr110.00 Cr128.00 Cr147.00 Cr139.00 Cr142.27 Cr105.76 Cr166.06 Cr180.89 Cr230.59 Cr
Interest Expense 2.00 Cr2.00 Cr2.00 Cr3.00 Cr5.00 Cr3.00 Cr3.00 Cr3.00 Cr3.44 Cr6.07 Cr5.82 Cr5.93 Cr6.31 Cr
Pretax Income 104.00 Cr97.00 Cr114.00 Cr113.00 Cr100.00 Cr120.00 Cr125.00 Cr143.00 Cr116.09 Cr76.60 Cr133.33 Cr150.62 Cr200.00 Cr
Tax Provision 21.84 Cr26.19 Cr29.64 Cr29.38 Cr23.00 Cr31.20 Cr27.50 Cr38.61 Cr25.37 Cr18.40 Cr34.20 Cr36.93 Cr50.97 Cr
Net Income 83.00 Cr70.00 Cr84.00 Cr83.00 Cr78.00 Cr89.00 Cr98.00 Cr105.00 Cr90.55 Cr58.32 Cr98.25 Cr113.20 Cr148.13 Cr
Diluted EPS 1.811.521.841.841.731.962.132.312.001.292.172.503.27

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 797.00 Cr893.00 Cr767.00 Cr913.00 Cr1,000.00 Cr1,134.00 Cr1,376.00 Cr-1,849.62 Cr2,174.20 Cr2,622.84 Cr2,950.94 Cr
Cost of Revenue --------958.08 Cr1,096.95 Cr1,143.74 Cr1,277.28 Cr
Gross Profit --------891.54 Cr1,077.24 Cr1,479.10 Cr1,673.66 Cr
Operating Expenses 612.00 Cr757.00 Cr722.00 Cr834.00 Cr868.00 Cr942.00 Cr1,037.00 Cr-578.64 Cr689.75 Cr1,029.81 Cr1,171.51 Cr
Operating Income 169.00 Cr108.00 Cr15.00 Cr51.00 Cr109.00 Cr165.00 Cr304.00 Cr-312.90 Cr387.50 Cr449.30 Cr502.15 Cr
EBITDA 185.00 Cr136.00 Cr45.00 Cr78.00 Cr132.00 Cr192.00 Cr340.00 Cr-395.25 Cr509.00 Cr599.01 Cr683.31 Cr
Interest Expense 16.00 Cr10.00 Cr7.00 Cr10.00 Cr10.00 Cr9.00 Cr8.00 Cr-5.75 Cr11.20 Cr11.66 Cr24.12 Cr
Pretax Income 156.00 Cr107.00 Cr15.00 Cr50.00 Cr104.00 Cr157.00 Cr302.00 Cr-337.65 Cr423.53 Cr503.97 Cr560.55 Cr
Tax Provision 43.68 Cr24.61 Cr3.60 Cr14.00 Cr23.92 Cr36.11 Cr63.42 Cr-72.33 Cr108.63 Cr121.35 Cr140.49 Cr
Net Income 112.00 Cr83.00 Cr11.00 Cr36.00 Cr80.00 Cr121.00 Cr239.00 Cr-266.31 Cr313.70 Cr380.57 Cr417.90 Cr
Diluted EPS 2.671.920.220.801.872.955.76-6.416.928.409.22

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 676.00 Cr722.00 Cr752.00 Cr731.00 Cr802.00 Cr902.00 Cr1,228.00 Cr-2,190.39 Cr2,680.95 Cr3,239.63 Cr3,860.90 Cr
Current Assets --------1,675.30 Cr1,862.49 Cr2,204.12 Cr2,722.74 Cr
Cash & Equivalents --------382.44 Cr403.28 Cr495.79 Cr634.14 Cr
Inventory --------484.74 Cr617.94 Cr845.52 Cr972.28 Cr
Receivables --------416.85 Cr453.18 Cr540.04 Cr644.57 Cr
Total Liabilities --------425.32 Cr595.05 Cr750.25 Cr808.22 Cr
Current Liabilities --------340.99 Cr389.85 Cr477.34 Cr527.09 Cr
Long Term Debt -------0----
Total Debt 101.00 Cr100.00 Cr110.00 Cr118.00 Cr100.00 Cr30.00 Cr34.00 Cr-122.94 Cr244.06 Cr321.91 Cr343.38 Cr
Total Equity 367.00 Cr442.00 Cr433.00 Cr471.00 Cr543.00 Cr636.00 Cr887.00 Cr-1,745.16 Cr2,065.05 Cr2,466.91 Cr3,023.16 Cr
Shares Outstanding --------45.32 Cr45.32 Cr45.32 Cr45.32 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow 155.00 Cr31.00 Cr14.00 Cr50.00 Cr27.00 Cr233.00 Cr179.00 Cr-237.41 Cr230.41 Cr206.66 Cr458.12 Cr
Investing Cash Flow -33.00 Cr-123.00 Cr-21.00 Cr-39.00 Cr-13.00 Cr-60.00 Cr-45.00 Cr--259.21 Cr-140.84 Cr-49.01 Cr-248.27 Cr
Financing Cash Flow 17.00 Cr-58.00 Cr-3.00 Cr3.00 Cr-21.00 Cr-114.00 Cr-15.00 Cr-197.83 Cr-68.73 Cr-65.15 Cr-70.93 Cr
Capital Expenditure -37.00 Cr-132.00 Cr-28.00 Cr-39.00 Cr-13.00 Cr-59.00 Cr-46.00 Cr--53.63 Cr-208.84 Cr-172.92 Cr-130.53 Cr
Free Cash Flow 118.00 Cr-101.00 Cr-14.00 Cr11.00 Cr14.00 Cr174.00 Cr133.00 Cr-183.78 Cr21.57 Cr33.74 Cr327.60 Cr
Net Change in Cash 138.00 Cr-150.00 Cr-10.00 Cr15.00 Cr-7.00 Cr60.00 Cr118.00 Cr-176.03 Cr20.84 Cr92.51 Cr138.93 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % --------48.2%49.5%56.4%56.7%
Operating Margin % 21.2%12.1%2.0%5.6%10.9%14.6%22.1%-16.9%17.8%17.1%17.0%
Net Margin % 14.1%9.3%1.4%3.9%8.0%10.7%17.4%-14.4%14.4%14.5%14.2%
ROE % 30.5%18.8%2.5%7.6%14.7%19.0%26.9%-15.3%15.2%15.4%13.8%
ROCE % --------16.9%16.9%16.3%15.1%

Shareholding Pattern

Insiders
43.87%
Institutions
18.34%
Public Float
32.67%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for MARKSANS

Google News Fri, 04 Sep 2026

Marksans Pharma Ltd. Stock News - Value Research

<a href="https://news.google.com/rss/articles/CBMif0FVX3lxTE9JaFhwRzdqOWlmUmt5bHpmVEdXM0VQSU9mYmk5a3hpSzZjWXlXdnZCUnROWkVUOVVxQV9zbXFULUhIelQycDkwZHNCbVZWamRIdVpyMS0wNTVSSEN6RHNUemZyOTRwZWUtMkplNElMRTRzVmU5VGhhZ25Wc3kyNmM?oc=5" target="_bla…

Google News Sun, 16 Aug 2026

Marksans Pharma Limited (NSE:MARKSANS) Looks Like A Good Stock, And It's Going Ex-Dividend Soon - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi7AFBVV95cUxOTnJqbXIyU2N2bGE0QjRzbkhxQlIwXzVPX2lMRjlMYnh1QVh6Qjh3c0haRW1BOTI2ZXVLMGlxd1VJY1J4amVuMDYwMGZCTk1lbUpXVXE4czVNcXhMdTE3emdCODZXd0diM083aWtBT0Q4RkttSEU5dmtuX09hSUZpQ1NBQjdCZnB0b0lPdj…

Google News Wed, 12 Aug 2026

Marksans Pharma Stock Jumps 11% After Net Profit Jumps 2.5x, Revenue Surges 36% - NDTV Profit

<a href="https://news.google.com/rss/articles/CBMi0gFBVV95cUxOUGNWalh3Q0lqdHB3ckNMdmhPZ1pjLU53bXIwYTlySmlCNVVOYzRpMl9FWVhBUXVPeDdkaFNBdU1nZHhFTEJqM3VHWnhOOHV6MDVfVDJJODdocmJLcWplRkJqa1JfcGU0Q2gwVEYtaUtRbDZnNVBrUEtyZ2JocmF1YlI1c0V1bXpFVC1DaF…

Google News Wed, 12 Aug 2026

Marksans Pharma shares rally over 9% after Q1 profit spikes 174% YoY to Rs 159 crore - The Economic Times

<a href="https://news.google.com/rss/articles/CBMi7AFBVV95cUxOQVE2SDZ5YUZlUWI5ZFRGb1BjeHVIUUs5SkV6N2QzdkR0RWJPMzB4TDVtZUl3VXVJSXdQZjYzVThYSkt2X0I0QmNPU0V3RURabS15VUROa3hsV0Z6ZzZKQmYzZVR2UTFJcndiMnJJc20wSkxjRi00RHdib0ZNeWVYSUoyYk9FcWlSSUM2RE…

Google News Wed, 12 Aug 2026

Marksans Pharma soars as Q1 PAT zooms 174% YoY - Business Standard

<a href="https://news.google.com/rss/articles/CBMixgFBVV95cUxPZVpkZ1dYckFidFpFMkJNMW9tdHJER3d3M3Q5TDVVVFJOSU1pVTZpV3ZkR052YTd2ZE5tZ212NWlYVmVXdWJhU0liNThxeFFLQ2xFOXBseVNIYjZUdy1HTVFOczVtZWxiTFhOd2hIYlppNTRnRUd2NDZMLWlLRzBoUHJOTkhmUVVfWWd6Ry…

Google News ue, 01 Sep 2026

Marksans Pharma to join Ashwamedh investor dialogue on September 2 - scanx.trade

<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxNWTlRc1ZZTDBpR29nR2NiLTJiR3B6eWZjY2t2eENjbDhpeTRxcjRrYXBjRjNkaUFNZHk3c1o3THV1OEk4OFBhSkt6V2JEZzlYTWVrQjEyZ1NBTm5Zc1Zucm5PZFJkNkNfYWtidGY0d3pfR1Btd3V0dkpKNXFQYnlNZ3RHT3hGZm1UcmJrM2…

MARKSANS — Frequently Asked Questions

What is the current share price of Marksans Pharma Limited (MARKSANS)?

As of 2026-09-08 04:53 IST, Marksans Pharma Limited (MARKSANS) trades at ₹326.75 on NSE. Its 52-week range is ₹156.46 to ₹332.50.

What is the market capitalisation of MARKSANS?

Marksans Pharma Limited (MARKSANS) has a market capitalisation of ₹14,807.13 Cr on NSE.

What is the P/E ratio of MARKSANS?

MARKSANS trades at a trailing price-to-earnings (P/E) ratio of 35.44. The industry average P/E is 41.64. Its price-to-book (P/B) ratio is 4.10.

Does MARKSANS pay a dividend?

Marksans Pharma Limited (MARKSANS) currently offers a dividend yield of 0.33%.

What is the return on equity (ROE) of MARKSANS?

MARKSANS has a return on equity (ROE) of 13.82%. Its return on capital employed (ROCE) is 17.54%.

Is MARKSANS a good stock to buy?

This page provides a data-driven analysis of Marksans Pharma Limited (MARKSANS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space